Effects of Evolocumab on Vitamin E and Steroid Hormone Levels: Results From the 52-Week, Phase 3, Double-Blind, Randomized, Placebo-Controlled DESCARTES Study
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Rationale : Vitamin E transport and steroidogenesis are closely associated with low-density lipoproteins (LDLs) metabolism, and evolocumab can lower LDL cholesterol (LDL-C) to low levels. Objective: To determine the effects of evolocumab on vitamin E and steroid hormone levels. Methods and Results: After titration of background lipid-lowering therapy per cardiovascular risk, 901 patients with an LDL-C ≥2.0 mmol/L were randomized to 52 weeks of monthly, subcutaneous evolocumab, or placebo. Vitamin E, cortisol, adrenocorticotropic hormone, and gonadal hormones were analyzed at baseline and week 52. In a substudy (n=100), vitamin E levels were also measured in serum, LDL, high-density lipoprotein, and red blood cell membranes at baseline and week 52. Absolute vitamin E decreased in evolocumab-treated patients from baseline to week 52 by 16% but increased by 19% when normalized for cholesterol. In the substudy, vitamin E level changes from baseline to week 52 mirrored the changes in the lipid fraction, and red blood cell membrane vitamin E levels did not change. Cortisol in evolocumab-treated patients increased slightly from baseline to week 52, but adrenocorticotropic hormone and the cortisol:adrenocorticotropic hormone ratio did not change. No patient had a cortisol:adrenocorticotropic hormone ratio <3.0 (nmol/pmol). Among evolocumab-treated patients, gonadal hormones did not change from baseline to week 52. Vitamin E and steroid changes were consistent across subgroups by minimum postbaseline LDL-C <0.4 and <0.6 mmol/L. Conclusions: As expected, vitamin E levels changed similarly to lipids among patients treated for 52 weeks with evolocumab. No adverse effects were observed in steroid or gonadal hormones, even at very low LDL-C levels. Clinical Trial Registration: URL: http://www.clinicaltrials.gov . Unique identifier: NCT01516879.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia
Blom, D. J., Hala, T., Bolognese, M., Lillestol, M. J., Toth, P. D., Burgess, L., Ceska, R., Roth, E., Koren, M. J., Ballantyne, C. M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1316222 · Cited by 720 · cited 3×
“The design and main results of this study have been published previously.(6) Men or women aged 18 to 75 years with an LDL-C ≥2.”
BackgroundMethodSelf-citationLambert (2012) · doi:10.1194/jlr.r026658 · Cited by 448
Bochem, A. E., Holleboom, A. G., Romijn, J. A., Hoekstra, M., Dallinga-Thie, G. M., Motazacker, M. M., Hovingh, G. K., Kuivenhoven, J. A., & Stroes, E. S. G. (2013) · Journal of Lipid Research · doi:10.1194/jlr.p033449 · Cited by 56
Cortisol: ACTH ratio to test for primary hypoadrenalism: a pilot study
Lee, M. K. V., Vasikaran, S., Doery, J. C. G., Wijeratne, N., & Prentice, D. (2013) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2012-131723 · Cited by 22 · cited 3×
“0 suggestive of primary hypoadrenalism.(14) We found no correlation between the change in LDL-C from baseline to week 52 and the corresponding change in cortisol (Online Figure I).”
BackgroundInfluential
Cited by
The Evolving Future of PCSK9 Inhibitors
Rosenson, R. S., Hegele, R. A., Fazio, S., & Cannon, C. P. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.04.054 · Cited by 264
“Fat-soluble vitamin concentrations (A, D, E, and K) and steroid hormones were measured as part of the prespecified safety analysis in phase II trials with PCSK9 inhibitors (118,121).”
MethodStatin non-adherence and residual cardiovascular risk: There is need for substantial improvement
Banach, M., Stulc, T., Dent, R., & Toth, P. P. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.09.075 · Cited by 197
Inhibiting PCSK9 — biology beyond LDL control
Stoekenbroek, R. M., Lambert, G., Cariou, B., & Hovingh, G. K. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0110-5 · Cited by 141
Evidence-based goals in LDL-C reduction
Soran, H., Dent, R., & Durrington, P. (2017) · Clinical Research in Cardiology · doi:10.1007/s00392-016-1069-7 · Cited by 92
Unmet Needs in LDL-C Lowering: When Statins Won’t Do!
Krähenbühl, S., Pavik-Mezzour, I., & von Eckardstein, A. (2016) · Drugs · doi:10.1007/s40265-016-0613-0 · Cited by 89
Metadata
- Authors
- Blom, D. J., Djedjos, C. S., Monsalvo, M. L., Bridges, I., Wasserman, S. M., Scott, R., & Roth, E.
- Venue
- Circulation Research
- Published
- 2015-09-25
- Volume
- 117
- Issue
- 8
- Pages
- 731-741
- ISSN
- 0009-7330 (ISSN-L)
- 1524-4571
- OpenAlex
- W2129809363
- Cited by
- 84
- References
- 6
- FWCI
- 13.33
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.